[{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":12,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Viatris"},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Telmisartan","moa":"AT-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Cosette Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Cosette Pharmaceuticals"},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Telmisartan","moa":"ACE","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Not Applicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Telmisartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Bisoprolol Fumarate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Apontis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Apontis Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"Closed Loop Medicine","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Amlodipine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Closed Loop Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Closed Loop Medicine \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Closed Loop Medicine \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telmisartan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"George Medicines \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Amlodipine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : GMRx2 is a triple combination of telmisartan, amlodipine and indapamide, in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.

                          Brand Name : GMRx2

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 06, 2024

                          Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Teva will use Closed Loop Medicine’s SaMD platform for personalized chronic disorder treatments like CLM-HT01.

                          Brand Name : CLM-HT01

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 26, 2024

                          Lead Product(s) : Amlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhag...

                          Brand Name : GMRx2

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 12, 2023

                          Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.

                          Brand Name : GMRx2

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 07, 2022

                          Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).

                          Brand Name : Biramlo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 19, 2022

                          Lead Product(s) : Bisoprolol Fumarate,Amlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Midas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The agreement outlines a transition period during which Daiichi Sankyo and Cosette will transfer responsibilities for the manufacture and commercialization of Azor, Benicar, Effient and other products, including quality assurance, pharmacovigilance and r...

                          Brand Name : Azor

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 18, 2022

                          Lead Product(s) : Amlodipine,Olmesartan Medoxomil

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Cosette Pharma

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.

                          Brand Name : GMRx2

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 01, 2021

                          Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Pfizer and Mylan have received clearance from the US FTC to advance the merger of Pfizer’s Upjohn generics unit and Mylan. As part of the FTC clearance, the companies need to divest seven products before moving forward with the merger, this includes Up...

                          Brand Name : Caduet

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 16, 2020

                          Lead Product(s) : Amlodipine,Atorvastatin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Viatris

                          Deal Size : $12,000.0 million

                          Deal Type : Merger

                          blank